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Abstract
Background: Infection with hepatitis B virus (HBV) is major public health concern. The limitations of available
antiviral drugs require development of novel approaches to inhibit HBV replication. This study was conducted to
identify functional elements and new siRNA target sites within the highly conserved regions of the 533 base post-
transcriptional regulatory element (PRE) of HBV RNAs.
Results: Computational analysis of the PRE sequence revealed several conserved regulatory elements that are
predicted to form local secondary structures some of these within known regulatory regions. A deletion analysis
showed that sub-elements of the PRE have different effects on the reporter activity suggesting that the PRE
contains multiple regulatory elements. Conserved siRNA targets at nucleotide position 1317-1337 and 1329-1349
were predicted. Although the siRNA at the position 1329-1349 had no effect on the expression of reporter gene,
the siRNA target site at the position 1317-1337 was observed to significantly decrease expression of the reporter
protein. This siRNA also specifically reduced the level of cccDNA in transiently HBV infected cells.
Conclusion: The HBV PRE is likely to contain multiple regulatory elements. A conserved target within this region at
1317-1337 is an effective siRNA target.
Introduction
H e p a t i t i sBv i r u s( H B V )i n f e c t i o ni sam a j o rc a u s eo f
hepatocellular carcinoma and liver cirrhosis worldwide
[1]. HBV vaccination can prevent new infections, but
effective antiviral drugs are required for the large num-
ber of HBV infected people. Current licensed therapies
such as interferon-a, lamivudine and adefovir dipivoxil
have been found to have many limitations. For example,
interferon-a is found to have a limited use for a narrow
range of patients and is associated with a number of
adverse effects whereas a long-term use of lamivudine
and adefovir dipivoxil could cause drug-resistant var-
iants of HBV [2]. Novel approaches for inhibiting HBV
replication are therefore urgently needed.
Currently, RNA interference (RNAi) has been emerged
as a potential technique for developing nucleic acid-
based gene silencing therapeutics for treatment of viral
diseases [3-7]. RNAi is a specific mechanism for down-
regulation of gene expression. It is evolutionally con-
served from plants to mammals. The RNAi process is
initiated by short double-stranded RNAs (dsRNAs) that
lead to the sequence-specific inhibition of their homolo-
gous genes [8]. Previous studies with HBV have shown
effective inhibition of HBV replication in mammalian
t i s s u ec u l t u r ea n di nam o u s em o d e lb yu s i n gs y n t h e t i c
small interfering RNAs (siRNAs) [9-11] and siRNA
expression plasmids, which the siRNAs are generated
from short hairpin RNA transcripts (shRNAs) and pro-
cessed into active siRNAs by Dicer in the cytoplasm of
cells [12-16].
The HBV genome contains four large overlapping
open reading frames that encode for five major pro-
teins namely core, large surface, middle surface, small
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may be generated by splicing or as regulatory small
reading frames [18]. Several sites located on different
HBV transcripts were demonstrated to be siRNA target
sites [15,19,20]. Mostly, these siRNA target sites were
predicted along the sequence of HBV genome using
bioinformatics programmes, which are based on certain
characteristics of ideal siRN A ss u c ha st w on u c l e o t i d e s
3′ overhang, low GC content (36-52%), base preference
at position 3, 10, 13 and 19, but not by the target
mRNA functionality [19,21,22]. This approach,
although effective, is limited as it does not consider
conservation in the genome. Therefore target sites,
although initially effective, might be able to be mutated
and the virus become resistant.
In this study, we were interested to identify siRNA
targets within the HBV post-transcriptional regulatory
element (HBV PRE), which is a cis-acting RNA element
approximately 500 bases long found in all HBV tran-
scripts. The PRE is a conserved RNA element [23] that
has been reported to be involved in the regulation of
HBV mRNAs including RNA splicing [24], RNA stability
[25] and nuclear export [26-2 8 ] .I na d d i t i o n ,i t sn u c l e a r
export is affected by myeloid differentiation primary
response protein 88 (MyD88) [29]. Several regulatory
elements have been identified within the PRE, including
a human La binding site [30,31], stem-loop structures,
HBV SLa and HBV SLb [32], a cis-acting splicing regu-
latory element (SRE-1) [24], the binding sites (PRE III)
of polypyrimidine tract binding protein (PTB) and gly-
ceraldehydes-3-phosphate dehydrogenase (GAPDH)
[33-36] (Figure 1A) and binding site of T-cell intracellu-
lar antigen 1 (TIA-1) [37], however, the core function of
the PRE remains unclear. This study was therefore
aimed to investigate potential siRNA target sites within
the PRE as well as the core functional elements of the
PRE.
Materials and methods
Bioinformatic analysis of functional elements
The functional elements within the PRE (nucleotides
1151-1684, of Accession number AM282986) were ana-
lyzed using results of CDS-Plotcon and Alidot pro-
grammes provided by the database HBVRegDB [23]. In
brief, a set of 32 completed HBV genomes were ana-
lysed by the CDS-Plotcon programme [38] to specifically
detect regulatory elements that are present within the
coding sequence. They were also analysed using the Ali-
dot programme [39] to determine conserved RNA sec-
ondary structures.
Figure 1 Prediction of conserved functional elements within the HBV PRE. (A) A schematic diagram of HBV PRE with annotation of
previously reported elements: human La-binding site (nucleotides 1275-1291) [30,31], a splicing regulatory element-1 (SRE-1) (nucleotides 1252-
1348), the conserved stem loop, HBV SLa (nucleotides 1292-1321) [32], the conserved stem loop HBV SLb (nucleotides 1411-1433) [32], a
subsection named PREIII (nucleotide 1485-1584) that was reported to bind to two cellular proteins in vitro, PTB and GAPDH [33,35]. The siRNA
target sites investigated in this study were also indicated (siRNA anti HBV PRE 1317-1337 and siRNA anti HBV PRE 1329-1349). (B) Detection of
putative functional elements within the PRE by CDS-plotcon. PRE sequences from selected human HBV genotypes A-H were input into the CDS-
plotcon programme. A high peak indicates conserved elements beyond that expected by coding. Four putative functional elements within HBV
PRE were detected, at 1151-1310, 1390-1450, 1515-1610 and 1540-1684. The diagram was produced by CDS-plotcon online (C) Detection of
conserved secondary RNA structures within the PRE. The same set of human HBV sequences was input into Alidot. The mountain plots indicate
regions that contain conserved RNA secondary structures at 1151-1410, 1410-1433, 1440-1500 and 1530-1620. The dashed boxes indicate
functional conserved elements that contain RNA secondary structures. The diagrams are to the same scale.
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The siRNA target sites within the PRE sequence were pre-
dicted using siExplorer [40], siDirect [41], and siRNA target
designer [42] programmes. Characteristics of desired siR-
NAs identified by Reynolds et al (2004) [22] were also
taken into consideration. Nucleotide blast (blastn) was per-
formed to check specificity of predicted siRNA target sites
against human genomic and human transcript databases
(Table 1 and additional file 1). The selected sequences were
chosen to target PRE positions 1317-1337 and 1329-1349.
Generation of luciferase reporter plasmids
An intronless reporter vector [pBasic (-IN)] was
constructed by removing the chimeric intron of the
Table 1 Overlapping prediction of siRNA target sites found within HBV PRE by different bioinformatics tools
Programme Position Sequence GC
(%)
Specificity (similarity %) Position base preference Reference
A3* T10* Non G13* A19*
siExplorer 1324-
1343
CAUCGGAACUGACAAUUCU 42.1 - 73% match ARP6 actin-related
protein 6 homolog transcript
1
- 79% match chromosome x
genomiccontig
2
T T C T [40]
1640-
1659
UGCCCAAGGUCUUACAUAA 42.1 - 74% match DIX domain containing
1 transcript
1
- 100% match chromosome X
genomic contig
2
CT T A
1641-
1660
GCCCAAGGUCUUACAUAAG 47.3 - 73% match DIX domain containing
1 transcript
1
- 95% match chromosome X
genomic contig
2
CC A G
siDirect 1344-
1366
TCGTCCTCTCGCGGAAATATACA 52 - 66% match oligophrenin 1 (OPHN1)
transcript
1
- 71% chromosome 16 open reading
frame 35
2
G C G A [41]
siRNA target
designer
1346-
1364
GTCCTCTCGCGGAAATATA 47 - 73% match oligophrenin 1 (OPHN1)
transcript
1
- 74% match hypothetical protein
LOC728975
2
C C A A [42]
1321-
1339
GCTCATCGGAACTGACAAT 47 - 74% ma1tch tetraspanin 7 (TSPAN7)
transcript
1
- 84% match chromosome 13 contig
2
TA T T
Reynolds
et al (2004)
1317-
1337*
AAAGCTCATCGGAACTGACAA 42 - 66% match tetraspanin 7 (TSPAN7)
transcript
1
- 81% match chromosome 2 genomic
contig
2
A C A C [22]
1318-
1338
AAGCTCATCGGAACTGACAAT 42 - 66% match tetraspanin 7 (TSPAN7)
transcript
1
- 95% match chromosome 17
genomic contig
2
GG A A
1329-
1349*
AACTGACAATTCTGTCGTCCT 42 - 76% match zinc finger protein 559
(ZNF559) transcript
1
- 76% match chromosome 19
genomic contig
2
CT T C
1336-
1356
AATTCTGTCGTCCTCTCGCGG 52 - 71% match F-box and leucine-rich
repeat protein 15 transcript
1
- 81% match chromosome 20
genomic contig
2
TG C C
1357-
1377
AAATATACATCGTTTCCATGG 33 - 62% match ADAM metallopeptidase
domain 12 (ADAM12) transcript
1
- 76% match chromosome 11
genomic contig
2
AT T T
1358-
1378
AATATACATCGTTTCCATGGC 42 - 67% match bactericidal/permeability
increasing protein-like 2 (BPIL2)
1
- 76% match chromosome 11
genomic contig
2
TC T G
Predicted siRNA target sites from siExplorer, siRNA target design and Reynolds et al. (2004) [22] were found to have overlapped regions. Bold indicates the
position base preference. ‘*’ indicates the selected siRNA target sites, ‘
1’ and ‘
2’ indicate the best matches from the blastn search against human transcript and
genomic databases respectively. Details of the blastn matches are in additional file 1.
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struct a splicing luciferase reporter vector (pSpliceLuc),
the parental vector, pGL3MS2site/Basic was modified to
place the luc+ gene between the splicing donor (SD)
and splicing acceptor (SA) sites. This modification
involved two-step cloning. The first cloning involved
amplification of the SD (forward: SV40+ 5′-ctgac-
taattttttttatttatgc-3′, reverse: SDR_AflII 5′-gaattcct-
taagccttaaacctgtcttgtaacc-3′) and then the amplification
o ft h eS As e q u e n c e( f o r w a r d :S A F _ X h o I5 ′-gaattcctcga-
gagaccaatagaaactgggc-3′, reverse: SAR_EcoRV 5′-gaattc-
gatatccctgtggagagaaaggcaaagtg-3′).
Amplification of the deletion series of the PRE
Three pairs of primers were specifically designed to
amplify three sub-sections of the HBV PRE: (i) full length
HBV PRE (forward: HBVPRE_1151F 5′-tctagagctagcttgct
cggcaacggcctggtctgtg-3′, reverse: HBVPRE_1684R 5′-
gccggcctcgaggacattgctgaga gtccaagagtcc-3′); (ii) HBV PRE
1399-1684 (forward: HBVPRE_1399F 5′-tctagagc tagctg-
gatccttcgcgggacgtcctttg-3′, reverse: HBVPRE_1684R 5′-
gccggcctcgagga cattgctgagagtccaagagtcc-3′) and (iii) HBV
PRE 1485-1584 (forward: HBV PRE_1485F 5′-tctagagc-
tagctcgtccccttctccgtct-3′, reverse: HBV PRE_1584R 5′-
gccgg cctcgaggtgcacacggaccggcagat-3′). The Amplification
was performed from a clone containing the complete HBV
genome (a gift from M-H Lin, National Taiwan Univer-
sity) using Expand™High Fidelity DNA polymerase
(Roche). Short fragments of the PRE 1292-1321 and HBV
PRE 1411-1433 were created by annealing synthetic oligo-
nucleotides: (i) forward: HBVSL_alpha oligoF 5′-ctag
cgttttgctcgcagccggtctggggcaaagcc-3′, reverse: HBVSL_al-
pha oligoR 5′-tcgaggctttgccccagaccggctgcgagcaaaacg-3′;
and (ii) forward: HBVSL_beta oligoF 5′-ctagcgg-
gacgtcctttgtttacgtcccc-3′, reverse: HBVSL_beta oligoR 5′-
tcgaggggacgtaaacaaaggacgtcccg-3′.
Generation of siRNA expression plasmids
Selected siRNA target sites at positions 1317-1337 and
1329-1349 were converted into shRNA template oligo-
nucleotides by adding the loop sequence, the target
site’s antisense strand and a termination signal for the
RNA pol III (Figure 2A). For cloning purposes, over-
hangs of half restriction enzyme sites for BamHI and
HindIII were flanked at the 5′-end and the 3′-end of the
template respectively. Sequences of the shRNA tem-
plates for targeting HBV PRE 1317-1337 and 1329-1349
were as follows: PRE1317 5′-gatccagctcatcggaactgacaatt-
caagagattgtcagttccgatgagctttttttggaaa-3′; 5AtPRE1317 5′-
agcttttccaaaaaaagctcatcggaactgacaatctcttgaattgtcagttcc-
gatgagctg-3′; PRE 1329 5′-gatccgctgacaattctgtcgtcctttcaa-
gagaaggacgacagaattgtcagttttttggaaa-3′; AtPRE1329 5′-
agcttttccaaaaaactgacaattctgtcgtccttctcttgaaaggacgaca-
gaattgtcagcg-3′. Then, the two complementary hairpin
siRNA oligonucleotides (each contains 1 μg/μL) were
annealed together and ligated with the cut pSilencer
3.0-H1 promoter vector (Ambion).
Western blot analysis
Cell lysates were separated on 4-12% Bis-Tris gel
(NuPAGE® Novex gel, InvitrogenTM Life Technologies)
and electrophoretically transferred onto polyvinylidene
difluoride (PVDF) membrane (Hybond-P, Amersham
Pharmacia Biotech). Blots were blocked with 5% of skim
milk in TBS-T buffer for 1 h and subsequently incubated
at 4°C for overnight with appropriate diluted primary anti-
bodies, anti-Luc (1:500, Roche), anti-GAPDH (1:2,500,
Ambion) and anti-PABP (1:10,000, Abcam). Then blot
was incubated with diluted horseradish peroxidase-conju-
gated secondary antibody, goat anti-mouse (1:10,000, BIO-
RAD) at room temperature for 1 h. For chemiluminescent
detection, the immuno-blot was applied with the ECL Plus
reagents (Amersham Pharmacia Biotech) and exposed to
X-ray films (HyperfilmTM, Amersham Bioscience) for 15
s - 10 min at room temperature. All exposed films were
then processed and qualified by imaging densitometry
(Molecular Analyst software).
Mammalian tissue culture and transfection
HuH-7, HepG2 and COS-7 cells were cultured in 75
cm
3 sterile tissue culture flasks (Greiner Bio-One) at 37°
Cw i t h5 %C O 2 in DMEM supplemented (Invitrogen)
with 10% heat inactivated FBS (10% v/v) (Invitrogen)
and 1% L-glutamine (Invitrogen). Prior to transfection,
cells were seeded on 24-well plates (Greiner Bio-One)
with a cell density approximately 1X 10
4 cells/mL and
incubated for 24 h. All transfection was performed using
FuGENE6 (Roche). The ratio between FuGENE6 (μL)
and DNA (μg) was 3:1. For deletion analysis, 195 ng of
the deletion series of HBV PRE reporter plasmids were
transiently co-transfected in quadruplicate with 5 ng of
the internal control plasmid (phRL-SV40: Promega, a
plasmid expressing humanized Renilla luciferase pro-
tein). pUC18 was used to top up the total amount of
DNA if required. For evaluating effect of siRNA expres-
sion plasmids, cells were co-transfected in triplicate with
95 ng pSpliceLuc/fPRE or pBasic (-IN)/fPRE, 5 ng of
phRL-SV40 and various amounts (0 ng, 300 ng, 600 ng
and 900 ng) of the siRNA expression plasmids. For
studying the siRNA effect of the pShRNA PRE 1317-
1337 on the luciferase protein, cells were transiently co-
transfected in triplicate with 45 ng of pSpliceLuc/fPRE
or pBasic (-IN)/fPRE, 5 ng of the phRL-SV40 and either
60 ng or 300 ng of the pShRNA PRE 1317-1337 con-
struct. The pSilencer-Negative was used to make up the
total of plasmid DNA to 350 ng. The pSilencer-GAPDH
was also included in the experiment as the positive con-
trol for the siRNA effect on the GAPDH protein.
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Forty-eight h post-transfection, cells were lysed with 100
μL of 1 × passive lysis buffer (Promega). Cell debris and
nuclei were removed by centrifugation and the superna-
tant was collected. The luciferase activity assay was per-
formed as described by Tanguay and Gallie (1996)
Quantitative real time- PCR analysis of HBV cccDNA
A plasmid expressing covalently closed HBV genome
(EMBL:AM282986) was constructed in pGEM-T Easy
Vector (Promega, Madison, WI) through a T-A cloning
strategy. Serial 10-fold dilutions of the cccDNA standard
plasmid from 10 to 10
10 copies/μL were detected by
real-time PCR assay and used to prepare the standard
curve for quantitation of HBV cccDNA. The standard
curve of HBV cccDNA was then constructed by plotting
the logarithm of the initial plasmid concentration
against the threshold cycle (Ct) obtained from each dilu-
tion. The standard plasmid DNA for quantitation was
included in each run as an external standard. HBV
Figure 2 The effect of siRNA expression plasmids on reporter activity. (A) ShRNA template oligonucleotides of siRNA anti PRE 1317-1337
and PRE 1329-1349. (B) The effects of pShRNA plasmids on luciferase activity. The line graphs indicate normalized luciferase activities of
transfected COS-7 cells with pSilencer-Negative, pSilencer-GAPDH, pShRNA PRE1317-1337 and pShRNA 1329-1349. COS-7 cells were transfected in
triplicate with 95 ng of pLucSplice/fPRE, 5 ng of phRL-SV40 and various amount of pSiRNA expression plasmids as indicated, pUC18 was used to
make up the total DNA to 1 μg. Cells were harvested at day 1, day 2 and day 3 post-transfection and analyzed for expression of luciferase
protein. ‘***’ indicates significant differences of normalized luciferase activities compared to 0 ng of siRNA expression plasmid with p < 0.001 (by
t-test). (C) The effect of pShRNA PRE1317-1337 on the luciferase activity in HuH-7 cells. In this experiment, cells were transiently transfected in
triplicate with 45 ng of the pSpliceLuc/fPRE, 5 ng of the phRL-SV40 and different amounts of the pShRNA constructs as indicated. pSilencer-
Negative was used to make up total DNA plasmid to 350 ng. Cells were harvested and analyzed luciferase activity and western blot analysis after
48 h of incubation. Reporter expression levels are higher from these SV40 promoter containing constructs in COS- 7 cells (B) than in Huh-7 cells
(C). The bar graph shows normalized luciferase activity of mean values of three independent experiments; error bars represent standard
deviation. ‘***’ indicates significant differences of normalized luciferase activities comparing to the control siRNA expression plasmid (pSilencer-
GAPDH) with p < 0.001 (by t-test). Western blot analysis with primary antibodies: anti-GAPDH, anti-firefly luciferase protein (anti-Luc) and anti-
Poly A binding protein (anti-PABP) and the horseradish peroxidase-conjugated secondary antibody.
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assay using the primers and probe as described pre-
viously [44]. The forward primer was HBV_CCC_F1 (5′-
actcttggactc cagcaatg-3′); the reverse primer was
HBV_CCC_R1 (5′-ctttatacgggtcaatgtcca-3′)a n dt h e
cccDNA specific probe was FAM-ttcaagcctc-
caagctgtgccttg-BHQ1. The optimized real-time PCR
reaction mixture comprised 1 μL of DNA template, 0.75
μM final concentration of each primer, 0.25 μLo ft h e
probe, 5 μLo f2×P l a t i n u mq P C RS u p e rM i x - U D G
(Invitrogen, California, USA), additional 2.5 mM MgCl2,
and nuclease-free water to a final volume of 10 μL. The
real-time PCR assay was carried out in a Rotor Gene
RG-3000 (Corbett Research, Australia) under the follow-
ing conditions: initial denaturing step at 95°C for 10
min, followed by 45 cycles of 95°C for 15 s and 61.5°C
for 1 min. Then the Rotor-Gene Software Version 6.0
(Corbett Research) was used for data acquisition and
analysis of the HBV cccDNA level. The result was indi-
cated in term of relative quantitation by comparative
threshold (delta-delta Ct) method (2
- ΔΔCt). The amount
of target gene in the sample, normalized to an endogen-
ous housekeeping gene (reference gene) and relative to
the normalized calibrator, is then given by 2
- ΔΔCt,
where
ΔΔ Δ Δ Ct Ct sample - Ct calibrator = () ( )
ΔCt (sample) = Ct (target gene of sample) - Ct (refer-
ence gene of sample)
ΔCt (calibrator) = Ct (target gene of calibrator) - Ct
(reference gene of calibrator)
Ratio (folds of difference) of sample: calibrator = 2
-
ΔΔCt
In this study, the reference gene was beta-globin, the
target gene was the cccDNA of HBV co-transfected
with siRNA, and the calibrator was cells transfected
with only the HBV plasmid.
Results and discussion
The HBV PRE was predicted to contain multiple functional
conserved elements
The HBV post-transcriptional regulatory element is
highly conserved among the mammalian hepadnaviridae
[23]. As the sequence of the PRE also encodes the P pro-
tein, the conservation may partly be due to constraints
on the encoded protein. This study therefore analyzed
functional core elements of the PRE using results gener-
ated by the CDS-plotcon programme, which scores con-
servation beyond what is required for coding [38] as well
as using programmes for predicting conserved RNA sec-
ondary structure [39]. CDS-plotcon indicated four con-
served elements within the functional PRE at nucleotide
positions 1151-1310, 1390-1450, 1515-1610 and 1540-
1684 (EMBL: AM282986, Figure 1B). Three of these
potential conserved regulatory elements were predicted
to form local RNA secondary structures by Alidot (Figure
1C). The results of both programmes therefore suggested
three putative functional conserved elements at nucleo-
tide positions 1151-1410, 1411-1433 and 1510-1620
(Dashed boxes, Figure 1).
Notably, the previously identified regulatory elements:
the human La binding site [30], SRE-1 [24] and HBV SL
alpha [32] are shown to be part of a large secondary
RNA structure within the predicted functional element
at the position 1151-1410 whereas the reported HBV SL
beta [32] and the PRE III [34,35] are part of the identi-
fied functional elements at the position 1411-1433 and
1520-1620 respectively (Figure 1). In addition, known
regulatory elements at the DNA level are also found to
be part of the region identified as the functional ele-
ments (high mountain peak) generated by the CDS-plot-
con such as the DNA enhancer 1 (nucleotide position
900-1310), the X promoter (nucleotide position 950-
1310), the DNA primer binding DR1 (nucleotide posi-
tion 1590-1600) and the DNA enhancer 2 (nucleotide
position 1636-1744) [45,46].
Taken together, the results support that the PRE is an
important regulatory region that contains multiple func-
tional conserved elements.
HBV PRE 1317-1377 is a novel siRNA target site
Although several sites in the HBV genome have pre-
viously been able to be targeted by siRNA, there is no
report of targets within this region of PRE. To predict
siRNA target sites, the sequence was analysed using
three programmes, siExplorer [40], siDirect [41] and
siRNA target designer [42]. In addition, the criteria of
ideal siRNAs reported by Reynolds et al (2004) [22]
were also taken into consideration. The predicted
siRNA target sites were checked for specificity using
nucleotide blast (blastn) against human genomic and
transcript databases. Predicted siRNA target sequences
that had more than 85% identity to human genomic
DNA or transcripts were designated as non-specific
siRNA targets and not used. As a result, an overlapping
region of predicted siRNA target sites was detected by
three different approaches (Table 1). Selected siRNA
target sites were chosen to cover this region, at nucleo-
tide position 1317-1337 and 1329-1349 (Figure 1A).
These two predicted siRNA sites were found within the
identified putative functional PRE element (nucleotide
position 1151-1410) and they are part of a large pre-
dicted conserved RNA secondary structure (Figure 1).
Selected siRNA target sites were converted into shRNA
template oligonucleotides (Figure 2A) and ligated with
the cut siRNA expression vector (pSilencer 3.0-H1,
Ambion). The generated siRNA expression plasmids
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pShRNA PRE 1329-1349. Subsequently, various amounts
(0 ng, 60ng, 300 ng, 600 ng and 900 ng) of the gener-
ated siRNA expression plasmids were transiently co-
transfected in triplicate with 95 ng of luciferase reporter
vector (pSpliceLuc/fPRE or pBasic (-IN)/fPRE) and 5 ng
of Renilla expression plasmid (phRL-SV40) using
FuGENE6. The experiment also included the positive
control shRNA plasmid (pSilencer-GAPDH, Ambion),
which targets the human GAPDH mRNA and the nega-
tive control plasmid (pSilencer-Negative, Ambion) a
scambled sequence that is not found in the human gen-
ome. Cells were harvested at different time points (1
day, 2 days, 3 days post-transfection).
The result shows that the pShRNA PRE 1317-1337
could specifically and significantly reduce the level of
luciferase activity at the day 2-time point (Figure 2B, p
< 0.001) even with a low amount (60 ng) of the siRNA
expression plasmid (Figure 2C). In contrast, the pre-
sence of pShRNA PRE 1329-1349 in different amounts
showed no effect on luciferase expression at any time
point (Figure 2B) although it was selected by similar cri-
teria and position to the effective siRNA target site
1317-1337 (Table 1 and Figure 1). Therefore, the results
suggest that specific properties of siRNA target sites are
more significant than others for effective targeting. The
level of pBasic (-IN)/fPRE was also significantly reduced
by this siRNA (60 ng, by 43% and 300 ng, by 79%).
Anti-HBV PRE 1317-1337 specifically reduced the level of
cccDNA in transiently HBV infected cells
This experiment was carried out to evaluate whether the
anti-HBV PRE 1317-1377 could also inhibit HBV repli-
cation in infected cells. This was done by measuring the
level of HBV covalently closed circular DNA (cccDNA)
in HepG2 cells that were transiently co-transfected with
30 ng of a HBV clone that expresses HBV and with 0
ng, 100 ng or 600 ng of the pShRNA PRE 1317-1377.
Forty eight h post-transfection, cells were harvested to
analyze the level of cccDNA using quantitative real time
PCR. The results indicated that the plasmid expressing
siRNA anti-HBV PRE 1317-1377 significantly reduced
the level of cccDNA in transiently infected cells (Figure
3, p < 0.001).
Previous reports showed that new formation of
cccDNA in transfected cells was directly controlled by
the expression of HBV transcripts [47,48]. As this
siRNA target site (HBV PRE 1317-1337) is present in all
HBV transcripts, it is possible that any or all HBV tran-
scripts were reduced by the siRNA, resulting in the
reduction of level of cccDNA.
Sub-sections of the PRE have different effects on the
reporter gene activity
To investigate the functional core elements of the PRE,
a deletion series of the PRE was designed based on
these predictions (CDS-plotcon and Alidot) and
Figure 3 The effect of pShRNA PRE 1317-1337 on the expression of cccDNA. Bar graphs indicate mean values of thresholds of three
independent experiments. In this study, HepG2 cells were transiently transfected in triplicate with 45 ng of the pSpliceLuc/fPRE, 5 ng of the
phRL-SV40 and different amounts of the pShRNA constructs as indicated. pSilencer-Negative was used to make up total DNA plasmid to 350 ng.
Cells were harvested and analyzed for luciferase activity and western blot analysis after 48 h of incubation. ‘***’ indicates significant differences of
comparative threshold comparing to the controls (positive cccDNA and cells without transfection of pShPRE 1317-1337) with p < 0.001 (by t-
test).
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alpha (nucleotide position 1291-1321), PRE III (nucleo-
tide position 1485-1584) (Figure 1). Each PRE subsec-
tion was then specifically generated by PCR and then
inserted into two different luciferase (luc+)r e p o r t e r
constructs digested at NheI and XhoI sites: (i) the spli-
cing luc+ reporter construct (pSpliceLuc), and (ii) the
intronless luciferase reporter construct [pBasic (-IN)]
(Figure 4A). Notably, the pSpliceLuc construct has the
luc+ gene within an intron, thus it could be used to
study whether the PRE could enhance the unspliced luc
+ gene expression. On the other hand, the pBasic (-IN)
reporter construct was designed to study functional
nuclear export of PRE by imitating the natural context
of the intronless HBV S transcript where PRE is located
the 3′ UTR of the gene. Subsequently, a deletion series
of the PRE reporter plasmids were transiently co-trans-
fected in quadruplicate with the phRL-SV40 vector in
HuH-7 and COS-7 cells.
The full length (fPRE) significantly enhanced unspliced
luc+ gene expression in both HuH-7 (Figure 4B, p <
0.001) and COS-7 cells (data not shown). This result
suggests that the fPRE either inhibit splicing or enhance
nuclear export, or both. Surprisingly, the PRE sub-sec-
tion 1399-1684 significantly inhibited unspliced luc+
gene expression (p < 0.001) whereas PRE sub-section
1292-1321 (HBV SL alpha), HBV PRE 1411-1433 (HBV
SL beta) and HBV PRE 1485-1584 (PRE III) did not
Figure 4 The effects of sub-sections of the PRE on reporter activity. (A) Schematic diagrams of Luc+ reporter constructs used in the study,
the splicing Luc+ reporter constructs (pSpliceLuc) and the intronless luciferase reporter construct (pBasic (-IN)). Sub-sections of the PRE were
indicated. Each HBV PRE sub-section was inserted into the pSpliceLuc vector at the NheI and XhoI sites. The numbering in the scheme
corresponds to nucleotide number of HBV adw2 genotype A (EMBL:AM282986). (B) The ratios of test firefly luciferase and control Renilla
luciferase proteins from the splicing luc+ reporter system (pSpliceLuc). (C) The ratios of firefly luciferase and Renilla luciferase proteins from the
intronless luc+ reporter system pBasic (-IN)). The pSpliceLuc constructs used in B require PRE dependent prevention of splicing out the reporter
from the intron, and thus have lower ratios than the intronless constructs used in C. In B and C, Cells were co-transfected with 195 ng of
luciferase reporter plasmids, 5 ng of Renilla reporter. Forty-eight h post-transfection, HuH-7 cells were harvested and 10 μL of these cell lysates
were assayed for expression of luciferase proteins using POLARstar OPTIMA (BMG Labtech). Each assay was repeated in triplicate. The mean
values and standard deviations of three independent experiments of the normalized luciferase activities are shown. Error bars represent standard
deviation. ‘*’, ‘***’ indicate significant differences of luciferase activities comparing to the control vector (pSpliceLuc) with p < 0.05 and p < 0.001
respectively.
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Page 8 of 10individually enhance the expression of unspliced luc+
(Figure 4B). This result was consistent with previous
published results, using the cat reporter system
(pDM138), this construct has a design similar to the
unspliced luc+ reporter construct used in this study.
The previous report indicated that duplication of HBV
SL beta and HBV SL alpha was required to enhance the
level of CAT activity in the cat reporter system
(pDM138) [26]. Indeed, six copies of HBV PRE III were
reported to increase the CAT activity (pDM138 reporter
system) in the same level as the full-length the PRE [49].
On the other hand, the results from the intronless luc
+ construct showed that none of the PRE sub-sections
including the fPRE were able to enhance the expression
of the intronless luc+ gene. Interestingly, the PRE sub-
section 1399-1684 also significantly inhibited the intron-
less luc+ gene whereas PRE alpha, PRE beta had no
effect on the expression of intronless luc+ gene (Figure
4C). Previously using northern blot analysis and primer
extension, the PRE has been shown to significantly
increase cytoplasmic export of the HBV S RNA [27,50].
It has also been reported to function in the context of
heterologous genes by enhancing expression of intron-
less transcripts of b-globin and c- myc [27,50-52]. In
this study, the PRE failed to increase activity of the
intronless Luc+ protein (Figure 4C). Therefore, experi-
mental results from this study provide evidence suggest-
ing that the ability of the PRE to enhance expression of
intronless transcripts is not applicable to all intronless
genes. It is possible that the PRE may not have an effect
o nt h eh i g h l ye x p r e s s e dg e n eluc+ whereas it did on
poorly expressed reporters (e.g. cat). Therefore, the
results of PRE deletion analysis from the intronless luc+
system might not be able to conclusively evaluate the
identified functional elements. Subsequent studies
should be conducted to test the function of these PRE
elements in a natural context using pgRNA (C and P
proteins) or surface (S) protein.
Interestingly, the PRE sub-section 1399-1684 signifi-
cantly reduced luciferase activity (Figure 4B, p < 0.001).
This result was also observed in the intronless luc+
reporter system (Figure 4C, p < 0.001). The result may
suggest either that the PRE sub-section 1399-1684 con-
tains a novel inhibitory element or that the PRE sub-
section 1151-1398 is an important element for the func-
tion of the PRE. Taken together, the PRE appears to
contain multiple weak regulatory elements, but some
aspects regarding the function of the PRE are still
unclear.
Conclusion
In summary, we showed that the HBV PRE contains the
effective siRNA target site (nucleotide position 1317-1337)
that when targeted with shRNA could reduce the level of
cccDNA in transiently transfected cells. However, more
experiments are required to optimize the duration and
efficiency of the siRNA effect. The computational and
deletion analysis suggested that the HBV PRE is likely to
contain several relatively weak regulatory elements that
vary in conservation. These elements may have different
functions during the HBV lifecycle.
Additional material
Additional file 1: Blastn matches for potential siRNAs targeting the
PRE region of HBV. The file contains blastn results of potential siRNA
target sites. The results indicate Score search, E-value and a list of
matched sequences and sequence alignments.
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